Breaking News

CTMX

CytomX Therapeutics

14
Jun

03/28/23 Mizuho: CytomX Therapeutics price target lowered to $2 from $4 at Mizuho

11/14/22 BMO Capital: CytomX Therapeutics downgraded to Market Perform from Outperform at BMO Capital

11/10/22 JPMorgan: JPMorgan double downgrades 'show-me-story' CytomX Therapeutics

11/10/22 JPMorgan: CytomX Therapeutics downgraded to Underweight from Overweight at JPMorgan

Clear This Search Refresh Search

Over a week ago Show Full Stories X To view all stories in expanded form, please subscribe. Get Free Trial Send Info
Earnings	CytomX Therapeutics reports Q1 EPS (5c), consensus (11c) » 17:12 05/09/23 05/09 17:12 05/09/23 17:12 CTMX CytomX Therapeutics $1.71 / +0.02 (+1.18%) Reports Q1 revenue… Reports Q1 revenue $23.5M, consensus $19.59M. "As we entered 2023, CytomX continued the advancement of our diversified portfolio of innovative Probody(R) therapeutic candidates for the treatment of cancer while ensuring disciplined resource allocation," said Sean McCarthy, D.Phil., chief executive officer and chairman of CytomX Therapeutics. "We remain intensely focused on execution towards key inflection points in our therapeutic pipeline including continued progress with CX-904 in Phase 1 and advancing our next-generation candidates, CX-2051 and CX-801, towards IND filings. Our scientific depth in conditional activation and biologics localization positions the company at the forefront of potential breakthroughs with potent biologic modalities such as ADCs, T-Cell engagers and cytokines. Additionally, our scientific leadership has attracted valued new relationships with Regeneron and Moderna, allowing us to maintain balance sheet strength. Moreover, with more than fifteen internal and partnered therapeutic programs, we are well positioned to deliver meaningful treatments to patients over time." ShowHide Related Items >><< Company News Street Research On The Fly Events CTMX CytomX Therapeutics $1.71 / +0.02 (+1.18%) 03/10/23 CytomX says exposure to any liquidity concern at SVB not 'significant' 01/26/23 CytomX announces milestone achievement in TCB collaboration with Astellas 01/05/23 CytomX Therapeutics updates business, announces 2023 relationship with Moderna 01/05/23 CytomX Therapeutics, Moderna announce strategic research collaboration CTMX CytomX Therapeutics $1.71 / +0.02 (+1.18%) 03/28/23 Mizuho CytomX Therapeutics price target lowered to $2 from $4 at Mizuho 11/14/22 BMO Capital CytomX Therapeutics downgraded to Market Perform from Outperform at BMO Capital 11/10/22 JPMorgan JPMorgan double downgrades 'show-me-story' CytomX Therapeutics 11/10/22 JPMorgan CytomX Therapeutics downgraded to Underweight from Overweight at JPMorgan CTMX CytomX Therapeutics $1.71 / +0.02 (+1.18%) 01/09/23 Biotech Alert: Searches spiking for these stocks today 01/06/23 Fly Intel: Pre-market Movers 01/05/23 Fly Intel: After-Hours Movers 11/21/22 Biotech Alert: Searches spiking for these stocks today 05/09/23 CytomX Therapeutics - CTMX 06/14/23 CytomX Therapeutics, Inc.

Over a month ago
Conference/Events	CytomX Therapeutics management to meet with Mizuho » 04:55 04/18/23 04/18 04:55 04/18/23 04:55 CTMX CytomX Therapeutics $1.72 / +0.055 (+3.31%) Meeting to be held in New… Meeting to be held in New York on April 18 hosted by Mizuho. ShowHide Related Items >><< Company News Street Research Earnings On The Fly Events CTMX CytomX Therapeutics $1.72 / +0.055 (+3.31%) 03/10/23 CytomX says exposure to any liquidity concern at SVB not 'significant' 01/26/23 CytomX announces milestone achievement in TCB collaboration with Astellas 01/05/23 CytomX Therapeutics updates business, announces 2023 relationship with Moderna 01/05/23 CytomX Therapeutics, Moderna announce strategic research collaboration CTMX CytomX Therapeutics $1.72 / +0.055 (+3.31%) 03/28/23 Mizuho CytomX Therapeutics price target lowered to $2 from $4 at Mizuho 11/14/22 BMO Capital CytomX Therapeutics downgraded to Market Perform from Outperform at BMO Capital 11/10/22 JPMorgan JPMorgan double downgrades 'show-me-story' CytomX Therapeutics 11/10/22 JPMorgan CytomX Therapeutics downgraded to Underweight from Overweight at JPMorgan CTMX CytomX Therapeutics $1.72 / +0.055 (+3.31%) 11/08/22 CytomX Therapeutics reports Q3 EPS (35), consensus (31c) CTMX CytomX Therapeutics $1.72 / +0.055 (+3.31%) 01/09/23 Biotech Alert: Searches spiking for these stocks today 01/06/23 Fly Intel: Pre-market Movers 01/05/23 Fly Intel: After-Hours Movers 11/21/22 Biotech Alert: Searches spiking for these stocks today 04/18/23 CytomX Therapeutics
Conference/Events	CytomX Therapeutics management to meet with Mizuho » 08:04 04/13/23 04/13 08:04 04/13/23 08:04 CTMX CytomX Therapeutics $1.63 / -0.065 (-3.85%) Meeting to be held in New… Meeting to be held in New York on April 18 hosted by Mizuho. ShowHide Related Items >><< Company News Street Research Earnings On The Fly Events CTMX CytomX Therapeutics $1.63 / -0.065 (-3.85%) 03/10/23 CytomX says exposure to any liquidity concern at SVB not 'significant' 01/26/23 CytomX announces milestone achievement in TCB collaboration with Astellas 01/05/23 CytomX Therapeutics updates business, announces 2023 relationship with Moderna 01/05/23 CytomX Therapeutics, Moderna announce strategic research collaboration CTMX CytomX Therapeutics $1.63 / -0.065 (-3.85%) 03/28/23 Mizuho CytomX Therapeutics price target lowered to $2 from $4 at Mizuho 11/14/22 BMO Capital CytomX Therapeutics downgraded to Market Perform from Outperform at BMO Capital 11/10/22 JPMorgan JPMorgan double downgrades 'show-me-story' CytomX Therapeutics 11/10/22 JPMorgan CytomX Therapeutics downgraded to Underweight from Overweight at JPMorgan CTMX CytomX Therapeutics $1.63 / -0.065 (-3.85%) 11/08/22 CytomX Therapeutics reports Q3 EPS (35), consensus (31c) CTMX CytomX Therapeutics $1.63 / -0.065 (-3.85%) 01/09/23 Biotech Alert: Searches spiking for these stocks today 01/06/23 Fly Intel: Pre-market Movers 01/05/23 Fly Intel: After-Hours Movers 11/21/22 Biotech Alert: Searches spiking for these stocks today 04/18/23 CytomX Therapeutics
Conference/Events	CytomX Therapeutics participates in a conference call with JPMorgan » 12:50 04/10/23 04/10 12:50 04/10/23 12:50 CTMX CytomX Therapeutics $1.59 / +0.025 (+1.60%) JPMorgan SMid Cap Biotech… JPMorgan SMid Cap Biotech Analyst Rama, along with CEO MCCarthy, participate in a conference call to be held on April 10 at 1 pm. Webcast Link ShowHide Related Items >><< Company News Street Research Earnings On The Fly Events CTMX CytomX Therapeutics $1.59 / +0.025 (+1.60%) 03/10/23 CytomX says exposure to any liquidity concern at SVB not 'significant' 01/26/23 CytomX announces milestone achievement in TCB collaboration with Astellas 01/05/23 CytomX Therapeutics updates business, announces 2023 relationship with Moderna 01/05/23 CytomX Therapeutics, Moderna announce strategic research collaboration CTMX CytomX Therapeutics $1.59 / +0.025 (+1.60%) 03/28/23 Mizuho CytomX Therapeutics price target lowered to $2 from $4 at Mizuho 11/14/22 BMO Capital CytomX Therapeutics downgraded to Market Perform from Outperform at BMO Capital 11/10/22 JPMorgan JPMorgan double downgrades 'show-me-story' CytomX Therapeutics 11/10/22 JPMorgan CytomX Therapeutics downgraded to Underweight from Overweight at JPMorgan CTMX CytomX Therapeutics $1.59 / +0.025 (+1.60%) 11/08/22 CytomX Therapeutics reports Q3 EPS (35), consensus (31c) CTMX CytomX Therapeutics $1.59 / +0.025 (+1.60%) 01/09/23 Biotech Alert: Searches spiking for these stocks today 01/06/23 Fly Intel: Pre-market Movers 01/05/23 Fly Intel: After-Hours Movers 11/21/22 Biotech Alert: Searches spiking for these stocks today 04/10/23 CytomX Therapeutics - CTMX 04/18/23 CytomX Therapeutics
Conference/Events	CytomX Therapeutics participates in a conference call with JPMorgan » 09:49 04/10/23 04/10 09:49 04/10/23 09:49 CTMX CytomX Therapeutics $1.56 / -0.005 (-0.32%) JPMorgan SMid Cap Biotech… JPMorgan SMid Cap Biotech Analyst Rama, along with CEO MCCarthy, participate in a conference call to be held on April 10 at 1 pm. Webcast Link ShowHide Related Items >><< Company News Street Research Earnings On The Fly Events CTMX CytomX Therapeutics $1.56 / -0.005 (-0.32%) 03/10/23 CytomX says exposure to any liquidity concern at SVB not 'significant' 01/26/23 CytomX announces milestone achievement in TCB collaboration with Astellas 01/05/23 CytomX Therapeutics updates business, announces 2023 relationship with Moderna 01/05/23 CytomX Therapeutics, Moderna announce strategic research collaboration CTMX CytomX Therapeutics $1.56 / -0.005 (-0.32%) 03/28/23 Mizuho CytomX Therapeutics price target lowered to $2 from $4 at Mizuho 11/14/22 BMO Capital CytomX Therapeutics downgraded to Market Perform from Outperform at BMO Capital 11/10/22 JPMorgan JPMorgan double downgrades 'show-me-story' CytomX Therapeutics 11/10/22 JPMorgan CytomX Therapeutics downgraded to Underweight from Overweight at JPMorgan CTMX CytomX Therapeutics $1.56 / -0.005 (-0.32%) 11/08/22 CytomX Therapeutics reports Q3 EPS (35), consensus (31c) CTMX CytomX Therapeutics $1.56 / -0.005 (-0.32%) 01/09/23 Biotech Alert: Searches spiking for these stocks today 01/06/23 Fly Intel: Pre-market Movers 01/05/23 Fly Intel: After-Hours Movers 11/21/22 Biotech Alert: Searches spiking for these stocks today 04/18/23 CytomX Therapeutics
Recommendations	CytomX Therapeutics price target lowered to $2 from $4 at Mizuho » 07:03 03/28/23 03/28 07:03 03/28/23 07:03 CTMX CytomX Therapeutics $1.79 / +0.09 (+5.29%) , ABBV AbbVie $157.49 / -0.57 (-0.36%) Mizuho analyst Mara… Mizuho analyst Mara Goldstein lowered the firm's price target on CytomX Therapeutics (CTMX) to $2 from $4 and keeps a Neutral rating on the shares. The company's Q4 report included AbbVie's (ABBV) decision to decline advancing CX-2029, leaving CytomX with an option to re-acquire rights, the analyst tells investors in a research note. CytomX has indicated this is under consideration, but the new price target reflects its removal, says the firm. ShowHide Related Items >><< Company News Street Research Earnings Periodicals On The Fly Events Options CTMX ABBV CTMX CytomX Therapeutics $1.79 / +0.09 (+5.29%) 03/10/23 CytomX says exposure to any liquidity concern at SVB not 'significant' 01/26/23 CytomX announces milestone achievement in TCB collaboration with Astellas 01/05/23 CytomX Therapeutics updates business, announces 2023 relationship with Moderna 01/05/23 CytomX Therapeutics, Moderna announce strategic research collaboration ABBV AbbVie $157.49 / -0.57 (-0.36%) 03/23/23 AbbVie advances clinical program of upadacitinib in SLE to Phase 3 03/23/23 AbbVie says Phase 3 INSPIRE study met primary, secondary endpoints 03/22/23 AbbVie receives CRL from FDA for NDA for ABBV-951 03/19/23 AbbVie announces late-breaking results for SKYRIZI study CTMX ABBV CTMX CytomX Therapeutics $1.79 / +0.09 (+5.29%) 11/14/22 BMO Capital CytomX Therapeutics downgraded to Market Perform from Outperform at BMO Capital 11/10/22 JPMorgan JPMorgan double downgrades 'show-me-story' CytomX Therapeutics 11/10/22 JPMorgan CytomX Therapeutics downgraded to Underweight from Overweight at JPMorgan 07/11/22 TD Cowen CytomX Therapeutics downgraded to Market Perform from Outperform at Cowen ABBV AbbVie $157.49 / -0.57 (-0.36%) 03/16/23 Chardan Immunome price target lowered to $8 from $9 at Chardan 03/01/23 Guggenheim Guggenheim starts AbbVie with a Buy on diversified growth 02/28/23 Guggenheim AbbVie initiated with a Buy at Guggenheim 02/22/23 BMO Capital AbCellera price target lowered to $32 from $40 at BMO Capital CTMX ABBV CTMX CytomX Therapeutics $1.79 / +0.09 (+5.29%) 11/08/22 CytomX Therapeutics reports Q3 EPS (35), consensus (31c) ABBV AbbVie $157.49 / -0.57 (-0.36%) 02/09/23 AbbVie sees Q1 adjusted EPS $2.39-$2.49, consensus $3.08 02/09/23 AbbVie sees FY23 revenue about $52B, consensus $54.21B 02/09/23 AbbVie sees FY23 adjusted EPS $10.70-$11.10, consensus $11.65 02/09/23 AbbVie reports Q4 adjusted EPS $3.60, consensus $3.56 ABBV ABBV AbbVie $157.49 / -0.57 (-0.36%) 02/06/23 AbbVie looking for next hit drug after competitors target Humira, WSJ reports 01/31/23 AbbVie's Humira drug faces competition in the U.S., FT reports 12/03/22 Buy AbbVie, stock still worth owning even as Humira fades, Barron's says 11/16/22 Optum Rx puts biosimilars on formulary against AbbVie's Humira, Bloomberg says CTMX ABBV CTMX CytomX Therapeutics $1.79 / +0.09 (+5.29%) 01/09/23 Biotech Alert: Searches spiking for these stocks today 01/06/23 Fly Intel: Pre-market Movers 01/05/23 Fly Intel: After-Hours Movers 11/21/22 Biotech Alert: Searches spiking for these stocks today ABBV AbbVie $157.49 / -0.57 (-0.36%) 03/22/23 What You Missed On Wall Street On Wednesday 03/22/23 What You Missed On Wall Street This Morning 03/01/23 Street Wrap: Today's Top 15 Upgrades, Downgrades, Initiations 02/22/23 What You Missed On Wall Street On Wednesday 05/21/23 PDUFA Date for Epcoritamab (DuoBody-CD3xCD20) 04/18/23 CytomX Therapeutics 05/05/23 AbbVie Inc. ABBV ABBV AbbVie $157.49 / -0.57 (-0.36%) 02/09/23 Unusually active option classes on open February 9th 01/18/23 Unusually active option classes on open January 18th 10/28/22 Unusually active option classes on open October 28th
Hot Stocks	CytomX says exposure to any liquidity concern at SVB not 'significant' » 15:41 03/10/23 03/10 15:41 03/10/23 15:41 CTMX CytomX Therapeutics $1.84 / -0.135 (-6.84%) , SIVB SVB Financial $105.92 / -0.04 (-0.04%) In a regulatory filing,… In a regulatory filing, CytomX (CTMX) stated that the company is aware of media reports indicating a possible liquidity concern at Silicon Valley Bank (SIVB). "CytomX does not consider its exposure to any liquidity concern at SVB to be significant. The cash held at SVB in CytomX's operating account is at or near the FDIC-insured limit of $250,000. CytomX also maintains a deposit account at SVB under a standby letter of credit issued pursuant to its office lease for approximately $917,000. Outside institutions serve as custodians for third-party investments held in CytomX's name which we believe are not directly exposed to any consequences of a liquidity concern at SVB," the company stated. ShowHide Related Items >><< Company News Street Research Earnings Syndicate Periodicals On The Fly Options SIVB CTMX SIVB SVB Financial $105.92 / -0.04 (-0.04%) 03/10/23 BioLife Solutions reports 'immaterial financial exposure' to Silicon Valley Bank 03/10/23 Reneo believes exposure to loss from SVB receivership is 'immaterial' 03/10/23 Omeros confirms absence of financial exposure to Silicon Valley Bank 03/10/23 Sunnova Energy reports 'minimal exposure' to Silicon Valley Bank CTMX CytomX Therapeutics $1.84 / -0.135 (-6.84%) 01/26/23 CytomX announces milestone achievement in TCB collaboration with Astellas 01/05/23 CytomX Therapeutics updates business, announces 2023 relationship with Moderna 01/05/23 CytomX Therapeutics, Moderna announce strategic research collaboration 11/17/22 Regeneron, CytomX Therapeutics announce research collaboration CTMX SIVB CTMX CytomX Therapeutics $1.84 / -0.135 (-6.84%) 11/14/22 BMO Capital CytomX Therapeutics downgraded to Market Perform from Outperform at BMO Capital 11/10/22 JPMorgan JPMorgan double downgrades 'show-me-story' CytomX Therapeutics 11/10/22 JPMorgan CytomX Therapeutics downgraded to Underweight from Overweight at JPMorgan 07/11/22 TD Cowen CytomX Therapeutics downgraded to Market Perform from Outperform at Cowen SIVB SVB Financial $105.92 / -0.04 (-0.04%) 03/10/23 Maxim SVB Financial downgraded to Sell from Buy at Maxim 03/10/23 Baird West Coast REITs underperforming on SVB news, says Baird 03/10/23 Stifel Stifel says SVB fallout 'appears limited' across firm's biotech coverage 03/10/23 GLJ Research Sunrun has lost two largest lenders in 90 days, says GLJ Research SIVB CTMX SIVB SVB Financial $105.92 / -0.04 (-0.04%) 01/19/23 SVB Financial reports Q4 EPS $4.62, consensus $5.27 10/20/22 SVB Financial reports Q3 EPS $7.21, consensus $6.95 CTMX CytomX Therapeutics $1.84 / -0.135 (-6.84%) 11/08/22 CytomX Therapeutics reports Q3 EPS (35), consensus (31c) 10 Mar SIVB SIVB SVB Financial $105.92 / -0.04 (-0.04%) 03/10/23 FDIC, Federal Reserve regulators at SVB Financial, Bloomberg reports 03/10/23 SVB could be rescued by government with no deal, WSJ reports 03/10/23 SVB Financial has staff work from home amid talks on next steps, Reuters reports 03/10/23 SVB deposit outflows outpacing sales process, CNBC reports SIVB CTMX SIVB SVB Financial $105.92 / -0.04 (-0.04%) 03/10/23 What You Missed On Wall Street This Morning 03/10/23 Street Wrap: Today's Top 15 Upgrades, Downgrades, Initiations 03/09/23 What You Missed On Wall Street On Thursday 03/09/23 What You Missed On Wall Street This Morning CTMX CytomX Therapeutics $1.84 / -0.135 (-6.84%) 01/09/23 Biotech Alert: Searches spiking for these stocks today 01/06/23 Fly Intel: Pre-market Movers 01/05/23 Fly Intel: After-Hours Movers 11/21/22 Biotech Alert: Searches spiking for these stocks today SIVB SIVB SVB Financial $105.92 / -0.04 (-0.04%) 02/02/23 Early notable gainers among liquid option names on February 2nd 01/20/23 Early notable gainers among liquid option names on January 20th 01/19/23 SVB Capital II options imply 7.1% move in share price post-earnings 12/29/22 Early notable gainers among liquid option names on December 29th

Over a quarter ago
Hot Stocks	CytomX announces milestone achievement in TCB collaboration with Astellas » 07:23 01/26/23 01/26 07:23 01/26/23 07:23 CTMX CytomX Therapeutics $2.63 / -0.115 (-4.20%) , ALPMY Astellas Pharma $15.17 / +0.1201 (+0.80%) CytomX Therapeutics… CytomX Therapeutics (CTMX) announced that it achieved a clinical candidate milestone under its t-cell engaging biospecific, TCB, agreement with Astellas (ALPMY). The clinical candidate is the first Probody TCB molecule to progress in the collaboration and will trigger a $5M dollar milestone payment to CytomX. CytomX and Astellas are also collaborating on additional conditionally activated TCB programs with CytomX eligible to receive future preclinical, clinical and commercial milestones. CytomX retains a cost share and co-commercialization option on a select number of targets."The progress with Astellas highlights our strategy to create value through a broad, diversified pipeline of wholly-owned and partnered therapeutic programs as well as expanding our research and development efforts in the field of TCBs. T-cell engaging therapies hold tremendous promise; however, the potency of this modality can lead to widespread activation of the immune system and a narrow therapeutic window. Localizing T-cell activity to the tumor microenvironment could result in important breakthroughs for patients, and the Probody platform has potential to address this challenge," said Sean McCarthy, D.Phil., chief executive officer and chairman of CytomX Therapeutics. ShowHide Related Items >><< Company News Street Research Earnings Periodicals On The Fly CTMX ALPMY CTMX CytomX Therapeutics $2.63 / -0.115 (-4.20%) 01/05/23 CytomX Therapeutics updates business, announces 2023 relationship with Moderna 01/05/23 CytomX Therapeutics, Moderna announce strategic research collaboration 11/17/22 Regeneron, CytomX Therapeutics announce research collaboration 09/12/22 CytomX Therapeutics announces Phase 1 data for anti-CTLA-4 probody ALPMY Astellas Pharma $15.17 / +0.1201 (+0.80%) 01/23/23 Novartis unit Sandoz to acquire Mycamine from Astellas 01/19/23 Astellas Pharma to present findings from Phase 3 SPOTLIGHT trial 01/19/23 Astellas Pharma: SBTi validates, approves company's GHG emissions targets 01/09/23 Selecta Biosciences, Astellas Pharma enter licensing agreement for IdeXork CTMX ALPMY CTMX CytomX Therapeutics $2.63 / -0.115 (-4.20%) 11/14/22 BMO Capital CytomX Therapeutics downgraded to Market Perform from Outperform at BMO Capital 11/10/22 JPMorgan JPMorgan double downgrades 'show-me-story' CytomX Therapeutics 11/10/22 JPMorgan CytomX Therapeutics downgraded to Underweight from Overweight at JPMorgan 07/11/22 TD Cowen CytomX Therapeutics downgraded to Market Perform from Outperform at Cowen ALPMY Astellas Pharma $15.17 / +0.1201 (+0.80%) 11/10/22 BTIG Taysha Gene Therapies price target lowered to $15 from $25 at BTIG 11/09/22 Truist Taysha cash overhang removed after Astellas investment, says Truist 10/26/22 Truist Taysha Gene Therapies price target lowered to $15 from $35 at Truist 08/10/22 Citi Astellas Pharma downgraded to Neutral from Buy at Citi CTMX CTMX CytomX Therapeutics $2.63 / -0.115 (-4.20%) 11/08/22 CytomX Therapeutics reports Q3 EPS (35), consensus (31c) 08/04/22 CytomX Therapeutics reports Q2 EPS (37c), consensus (36c) ALPMY ALPMY Astellas Pharma $15.17 / +0.1201 (+0.80%) 08/23/22 Astellas seeks regulatory review of hot flash drug in Europe, Bloomberg report CTMX ALPMY CTMX CytomX Therapeutics $2.63 / -0.115 (-4.20%) 01/09/23 Biotech Alert: Searches spiking for these stocks today 01/06/23 Fly Intel: Pre-market Movers 01/05/23 Fly Intel: After-Hours Movers 11/21/22 Biotech Alert: Searches spiking for these stocks today ALPMY Astellas Pharma $15.17 / +0.1201 (+0.80%) 08/23/22 What You Missed On Wall Street This Morning
On The Fly	Biotech Alert: Searches spiking for these stocks today » 11:11 01/09/23 01/09 11:11 01/09/23 11:11 BLPH Bellerophon $2.13 / -0.23 (-9.75%) , ZLAB Zai Lab $44.28 / -1.66 (-3.61%) , ORTX Orchard Therapeutics / + , CTMX CytomX Therapeutics $2.78 / +0.265 (+10.56%) , FGEN FibroGen $19.91 / +0.13 (+0.66%) , NVCR Novocure $93.01 / -15.92 (-14.61%) These names in the… Open Full Text ShowHide Related Items >><< Company News Street Research Earnings Periodicals On The Fly Events ZLAB ORTX NVCR FGEN CTMX BLPH ZLAB Zai Lab $44.28 / -1.66 (-3.61%) 01/09/23 Zai Lab appoints Michel Vounatsos to board of directrs 01/05/23 Zai Lab, Novocure announces LUNAR study met primary overall survival endpoint 01/03/23 Zai Lab appoinst Amado as President, Head of Global Oncology R&D 12/15/22 Zai Lab presents new interim OS data from NORA study ORTX Orchard Therapeutics / + 01/09/23 Orchard Therapeutics provides FY23 key milestones 01/05/23 Orchard announces U.S. FDA clearance of IND application for OTL-203 12/12/22 Orchard Therapeutics announces early results from PoC study of OTL-201 12/01/22 Orchard Therapeutics announces Swissmedic Validation of MAA for Libmeldy NVCR Novocure $93.01 / -15.92 (-14.61%) 01/05/23 Novocure announces LUNAR study met primary endpoint 11/29/22 Novocure's Optune approved in Canada for recurrent glioblastoma 11/11/22 Novocure receives CE Mark for flex array FGEN FibroGen $19.91 / +0.13 (+0.66%) 08/26/22 FibroGen announces completion of patient enrollment in MATTERHORN CTMX CytomX Therapeutics $2.78 / +0.265 (+10.56%) 01/05/23 CytomX Therapeutics updates business, announces 2023 relationship with Moderna 01/05/23 CytomX Therapeutics, Moderna announce strategic research collaboration 11/17/22 Regeneron, CytomX Therapeutics announce research collaboration 09/12/22 CytomX Therapeutics announces Phase 1 data for anti-CTLA-4 probody BLPH Bellerophon $2.13 / -0.23 (-9.75%) 01/05/23 Bellerophon announces license agreement for commercialization of INOpulse 09/27/22 Bellerophon announces FDA acceptance of change to ongoing Phase 3 REBUILD study BLPH ZLAB ORTX CTMX FGEN NVCR BLPH Bellerophon $2.13 / -0.23 (-9.75%) 04/04/22 Brookline Bellerophon price target lowered to $19 from $26 at Brookline ZLAB Zai Lab $44.28 / -1.66 (-3.61%) 11/11/22 Citi Zai Lab price target lowered to $127 from $199 at Citi 08/09/22 Citi Zai Lab price target raised to $199 from $193 at Citi 05/12/22 Citi Zai Lab price target lowered to $193 from $198 at Citi 03/17/22 Citi Citi opens '90-day positive Catalyst Watch' on Zai Lab ORTX Orchard Therapeutics / + 07/18/22 Oppenheimer Orchard Therapeutics assumed with an Outperform at Oppenheimer 05/13/22 Barclays Orchard Therapeutics price target lowered to $4 from $6 at Barclays 03/31/22 SMBC Nikko Orchard Therapeutics downgraded to Neutral from Outperform at SMBC Nikko 03/31/22 Stifel Orchard Therapeutics price target lowered to $5 from $12 at Stifel CTMX CytomX Therapeutics $2.78 / +0.265 (+10.56%) 11/14/22 BMO Capital CytomX Therapeutics downgraded to Market Perform from Outperform at BMO Capital 11/10/22 JPMorgan JPMorgan double downgrades 'show-me-story' CytomX Therapeutics 11/10/22 JPMorgan CytomX Therapeutics downgraded to Underweight from Overweight at JPMorgan 07/11/22 TD Cowen CytomX Therapeutics downgraded to Market Perform from Outperform at Cowen FGEN FibroGen $19.91 / +0.13 (+0.66%) 01/05/23 BofA FibroGen upgraded to Buy at BofA ahead of pamrev trial data 01/05/23 BofA FibroGen upgraded to Buy from Neutral at BofA NVCR Novocure $93.01 / -15.92 (-14.61%) 01/06/23 Piper Sandler Medicare paying 9% more for Novocure's Optune system in 2023, says Piper 01/06/23 Wells Fargo Novocure downgraded to Equal Weight from Overweight at Wells Fargo 01/05/23 H.C. Wainwright Novocure price target raised to $140 from $100 at H.C. Wainwright 01/03/23 Evercore ISI Novocure added to 'TAP Underperform' list at Evercore ISI ZLAB ORTX NVCR FGEN CTMX BLPH ZLAB Zai Lab $44.28 / -1.66 (-3.61%) 11/09/22 Zai Lab reports Q3 EPS ($1.68), consensus ($1.25) 08/09/22 Zai Lab reports Q2 EPS ($1.44), consensus (94c) ORTX Orchard Therapeutics / + 01/09/23 Orchard Therapeutics sees Q4 Libmeldy sales $5.8M 11/14/22 Orchard Therapeutics reports Q3 EPS (37c), consensus (24c) 08/04/22 Orchard Therapeutics reports Q2 EPS (40c) vs. (29c) last year NVCR Novocure $93.01 / -15.92 (-14.61%) 01/09/23 Novocure sees Q4 revenue $128M, consensus $129.14M 10/27/22 Novocure reports Q EPS (25c), consensus (26c) 07/28/22 Novocure reports Q2 EPS (23c), consensus (15c) FGEN FibroGen $19.91 / +0.13 (+0.66%) 11/07/22 FibroGen reports Q3 EPS (98c), consensus (81c) 08/08/22 FibroGen reports Q2 EPS (78c), consensus (94c) CTMX CytomX Therapeutics $2.78 / +0.265 (+10.56%) 11/08/22 CytomX Therapeutics reports Q3 EPS (35), consensus (31c) 08/04/22 CytomX Therapeutics reports Q2 EPS (37c), consensus (36c) BLPH Bellerophon $2.13 / -0.23 (-9.75%) 11/14/22 Bellerophon reports Q3 EPS (53c), consensus (58c) 08/15/22 Bellerophon reports Q2 EPS (43c) vs (36c) last year ZLAB ZLAB Zai Lab $44.28 / -1.66 (-3.61%) 09/07/22 SEC cautions Chinese companies about risks of auditor changes, WSJ reports ZLAB NVCR CTMX ZLAB Zai Lab $44.28 / -1.66 (-3.61%) 01/05/23 What You Missed On Wall Street On Thursday 01/05/23 What You Missed On Wall Street This Morning 11/09/22 Fly Intel: After-Hours Movers NVCR Novocure $93.01 / -15.92 (-14.61%) 01/06/23 Street Wrap: Today's Top 15 Upgrades, Downgrades, Initiations CTMX CytomX Therapeutics $2.78 / +0.265 (+10.56%) 01/06/23 Fly Intel: Pre-market Movers 01/05/23 Fly Intel: After-Hours Movers 11/21/22 Biotech Alert: Searches spiking for these stocks today 11/10/22 What You Missed On Wall Street On Thursday 01/12/23 41st Annual Healthcare Conference 02/23/23 Novocure - NVCR
On The Fly	Fly Intel: Pre-market Movers » 09:02 01/06/23 01/06 09:02 01/06/23 09:02 BVXV BiondVax $3.08 / +0.08 (+2.67%) , SPRB Spruce Biosciences $1.26 / +0.03 (+2.44%) , CTMX CytomX Therapeutics $1.80 / +0.125 (+7.49%) , DCT Duck Creek Technologies $11.28 / -0.27 (-2.34%) , AUPH Aurinia Pharmaceuticals $6.88 / +0.165 (+2.46%) , AEHR Aehr Test Systems $17.28 / -0.62 (-3.46%) , TSLA Tesla $110.35 / -3.3 (-2.90%) , BBBY Bed Bath & Beyond $1.69 / -0.725 (-30.08%) , LUV Southwest $33.53 / -0.09 (-0.27%) , NVCR Novocure $118.46 / +47.98 (+68.08%) , FATE Fate Therapeutics $10.97 / -0.185 (-1.66%) , MRNA Moderna $173.53 / -3.87 (-2.18%) , JNJ Johnson & Johnson $178.77 / -1.39 (-0.77%) Check out this morning's… Open Full Text ShowHide Related Items >><< Company News Street Research Earnings Periodicals On The Fly Events Options TSLA SPRB NVCR MRNA LUV JNJ FATE DCT CTMX BVXV BBBY AUPH AEHR TSLA Tesla $110.35 / -3.3 (-2.90%) 01/04/23 Cathie Wood's ARK Investment bought 21K shares of Tesla today 01/03/23 Cathie Wood's ARK Investment bought 176K shares of Tesla today 01/03/23 Piedmont Lithium jumps 9% to $47.99 after amended pact with Tesla 01/03/23 Piedmont Lithium amends agreement with Tesla SPRB Spruce Biosciences $1.26 / +0.03 (+2.44%) 01/05/23 Spruce Biosciences jumps almost 100% after licensing deal for tildacerfont 01/05/23 Spruce Biosciences, Kaken Pharma enter exclusive agreement for Tildacerfont NVCR Novocure $118.46 / +47.98 (+68.08%) 01/05/23 Zai Lab, Novocure announces LUNAR study met primary overall survival endpoint 01/05/23 Novocure announces LUNAR study met primary endpoint 11/29/22 Novocure's Optune approved in Canada for recurrent glioblastoma 11/11/22 Novocure receives CE Mark for flex array MRNA Moderna $173.53 / -3.87 (-2.18%) 01/04/23 Moderna to acquire OriCiro Genomics for $85M 12/26/22 Fly Intel: Top five weekend stock stories LUV Southwest $33.53 / -0.09 (-0.27%) 01/06/23 Southwest reports preliminary Q4 capacity down 6% vs. 4Q19 01/06/23 Southwest canceled more than 16,700 flights from December 21-December 31 01/06/23 Southwest expects to report net loss in Q4 01/06/23 Southwest expects to report net loss in Q4 JNJ Johnson & Johnson $178.77 / -1.39 (-0.77%) 01/06/23 Alkermes reports interim award in arbitration proceedings with Janssen 12/22/22 Steel Dynamics to replace Abiomed in S&P 500 at open on 12/22 FATE Fate Therapeutics $10.97 / -0.185 (-1.66%) 01/05/23 Fate Therapeutics down 45% on termination of collaboration pact with Janssen 01/05/23 Fate Therapeutics trading resumes 01/05/23 Fate Therapeutics trading halted, news pending 12/13/22 Fate Therapeutics announces data on approaches to cancer immunotherapies DCT Duck Creek Technologies $11.28 / -0.27 (-2.34%) 01/05/23 Duck Creek Technologies to acquire Imburse Payments 12/05/22 Duck Creek Technologies announces Copart has joined its partner ecosystem 11/10/22 Duck Creek Technologies announces Mutual Benefit will utilize its SaaS solution 10/31/22 Duck Creek Technologies announces automated test integration with SPLICE CTMX CytomX Therapeutics $1.80 / +0.125 (+7.49%) 01/05/23 CytomX Therapeutics updates business, announces 2023 relationship with Moderna 01/05/23 CytomX Therapeutics, Moderna announce strategic research collaboration 11/17/22 Regeneron, CytomX Therapeutics announce research collaboration 09/12/22 CytomX Therapeutics announces Phase 1 data for anti-CTLA-4 probody BVXV BiondVax $3.08 / +0.08 (+2.67%) 01/06/23 BiondVax announces results of preclinical study of inhaled COVID-19 therapy 12/30/22 BiondVax CEO says set the stage in 2022 for 'highly successful' 2023 12/16/22 BiondVax trading resumes 12/16/22 BiondVax trading halted, volatility trading pause BBBY Bed Bath & Beyond $1.69 / -0.725 (-30.08%) 01/05/23 Bed Bath & Beyond CEO says Q3 performance hurt by inventory constraints 01/05/23 Bed Bath & Beyond down 13% after 'going concern' warning 01/05/23 Bed Bath & Beyond warns on 'substantial doubt' about remaining a 'going concern' 12/23/22 Bed Bath & Beyond reports Rosenzweig voluntarily resigned from board AUPH Aurinia Pharmaceuticals $6.88 / +0.165 (+2.46%) 01/03/23 Aurinia Pharmaceuticals enters patent settlement pact with Sun Pharmaceutical 11/30/22 Aurinia announces U.K. marketing authorization of Lupkynis 09/19/22 Aurinia announces European Commission approval of LUPKYNIS 07/26/22 Aurinia says USPTO to institute trial on Inter Partes review of Lupkynis patent AEHR Aehr Test Systems $17.28 / -0.62 (-3.46%) 01/05/23 Aehr Test Systems jumps 14% after Q2 earnings beat, production order 01/05/23 Aehr Test Systems announces follow on order from silicon carbide chip client 12/07/22 Aehr Test Systems receives inital production order for FOX-XP multi-wafer test 11/04/22 Aehr Test Systems receives over $4M in orders for FOX WaferPak BVXV SPRB CTMX DCT AUPH AEHR TSLA BBBY LUV NVCR FATE MRNA JNJ BVXV BiondVax $3.08 / +0.08 (+2.67%) 01/26/22 Aegis BiondVax initiated with a Buy at Aegis SPRB Spruce Biosciences $1.26 / +0.03 (+2.44%) 11/17/22 Oppenheimer Spruce Biosciences price target lowered to $8 from $13 at Oppenheimer 11/16/22 JMP Securities Spruce Biosciences initiated with an Outperform at JMP Securities 03/08/22 Ladenburg Spruce Biosciences initiated with a Buy at Ladenburg CTMX CytomX Therapeutics $1.80 / +0.125 (+7.49%) 11/14/22 BMO Capital CytomX Therapeutics downgraded to Market Perform from Outperform at BMO Capital 11/10/22 JPMorgan JPMorgan double downgrades 'show-me-story' CytomX Therapeutics 11/10/22 JPMorgan CytomX Therapeutics downgraded to Underweight from Overweight at JPMorgan 07/11/22 TD Cowen CytomX Therapeutics downgraded to Market Perform from Outperform at Cowen DCT Duck Creek Technologies $11.28 / -0.27 (-2.34%) 01/04/23 BofA Duck Creek Technologies downgraded to Underperform from Neutral at BofA 12/29/22 Raymond James Duck Creek 2023 outlook 'much improved' on relative basis, says Raymond James 12/12/22 RBC Capital Coupa Software upgraded to Sector Perform from Underperform at RBC Capital 12/01/22 JPMorgan Duck Creek Technologies initiated with a Neutral at JPMorgan AUPH Aurinia Pharmaceuticals $6.88 / +0.165 (+2.46%) 01/03/23 RBC Capital Aurinia price target raised to $11 from $10 at RBC Capital 11/07/22 H.C. Wainwright Aurinia Pharmaceuticals price target lowered to $14 from $26 at H.C. Wainwright 11/04/22 Oppenheimer Oppenheimer downgrades Aurinia on commercial challenges 11/04/22 Oppenheimer Aurinia Pharmaceuticals downgraded to Perform from Outperform at Oppenheimer AEHR Aehr Test Systems $17.28 / -0.62 (-3.46%) 10/17/22 William Blair Aehr Test Systems initiated with an Outperform at William Blair TSLA Tesla $110.35 / -3.3 (-2.90%) 01/05/23 Edward Jones Edward Jones upgrades Tesla on long-term growth opportunities 01/05/23 Edward Jones Tesla upgraded to Buy from Hold at Edward Jones 01/05/23 Mizuho Tesla price target lowered to $250 from $285 at Mizuho 01/04/23 Truist Rivian Automotive price target lowered to $50 from $65 at Truist BBBY Bed Bath & Beyond $1.69 / -0.725 (-30.08%) 01/05/23 Wells Fargo Wells halves Bed Bath & Beyond target to $1, says bankruptcy may be 'imminent' 11/28/22 Wedbush Black Friday winners Include Best Buy, losers include Pets, says Wedbush 09/30/22 Odeon Capital Odeon upgrades Bed Bath & Beyond to Hold with things 'moving in right direction' 09/30/22 Odeon Capital Bed Bath & Beyond upgraded to Hold from Sell at Odeon Capital LUV Southwest $33.53 / -0.09 (-0.27%) 12/16/22 Goldman Sachs Southwest resumed with a Neutral at Goldman Sachs 12/15/22 TD Cowen Copa Holdings upgraded to Outperform at Cowen amid airlines rating shake-up 12/08/22 Susquehanna Southwest guidance suggests risk around order book, says Susquehanna 12/08/22 Deutsche Bank Southwest price target raised to $62 from $60 at Deutsche Bank NVCR Novocure $118.46 / +47.98 (+68.08%) 01/06/23 Wells Fargo Novocure downgraded to Equal Weight from Overweight at Wells Fargo 01/05/23 H.C. Wainwright Novocure price target raised to $140 from $100 at H.C. Wainwright 01/03/23 Evercore ISI Novocure added to 'TAP Underperform' list at Evercore ISI 11/29/22 Wells Fargo Novocure upgraded to Overweight into lung cancer study at Wells Fargo FATE Fate Therapeutics $10.97 / -0.185 (-1.66%) 01/06/23 Truist Truist cuts Fate Therapeutics to Hold after discontinuing Janssen collaboration 01/06/23 BofA Fate Therapeutics double downgraded to Underperform at BofA 01/06/23 BofA Fate Therapeutics downgraded to Underperform from Buy at BofA 01/06/23 Wedbush Fate Therapeutics downgraded to Neutral from Outperform at Wedbush MRNA Moderna $173.53 / -3.87 (-2.18%) 01/05/23 Morgan Stanley Morgan Stanley sees Moderna's phase 3 RSV vaccine data as catalyst-driven idea 12/20/22 Piper Sandler Moderna price target raised to $217 from $214 at Piper Sandler 12/19/22 Jefferies Moderna upgraded to Buy from Hold at Jefferies 12/16/22 Morgan Stanley Moderna price target raised to $209 from $170 at Morgan Stanley JNJ Johnson & Johnson $178.77 / -1.39 (-0.77%) 01/06/23 BMO Capital Fate Therapeutics downgraded to Market Perform from Outperform at BMO Capital 01/03/23 Wells Fargo Wells Fargo upgrades Immunovant to Overweight, raises price target to $27 TSLA SPRB NVCR MRNA LUV JNJ FATE DCT CTMX BVXV BBBY AUPH AEHR TSLA Tesla $110.35 / -3.3 (-2.90%) 10/19/22 Tesla reports Q3 EPS $1.05, consensus 99c 10/19/22 Notable companies reporting after market close 07/20/22 Tesla reports Q2 EPS $2.27, consensus $1.85 07/20/22 Notable companies reporting after market close SPRB Spruce Biosciences $1.26 / +0.03 (+2.44%) 08/10/22 Spruce Biosciences reports Q2 EPS (51c), consensus (54c) NVCR Novocure $118.46 / +47.98 (+68.08%) 10/27/22 Novocure reports Q EPS (25c), consensus (26c) 07/28/22 Novocure reports Q2 EPS (23c), consensus (15c) MRNA Moderna $173.53 / -3.87 (-2.18%) 11/03/22 Moderna reports Q3 EPS $2.53, consensus $3.29 11/02/22 Notable companies reporting before tomorrow's open 08/03/22 Moderna reports Q2 GAAP EPS $5.24, consensus $4.55 LUV Southwest $33.53 / -0.09 (-0.27%) 10/27/22 Southwest sees FY22 ASMs down 4.5% 10/27/22 Southwest sees Q4 revenue up 13%-17%, consensus $6.23B 10/27/22 Southwest reports Q3 adjusted EPS 50c, consensus 42c 10/26/22 Notable companies reporting before tomorrow's open JNJ Johnson & Johnson $178.77 / -1.39 (-0.77%) 10/18/22 Johnson & Johnson cuts FY22 estimated reported sales view to $93.0B-$93.5B 10/18/22 Johnson & Johnson narrows FY22 adjusted operational EPS view to $10.70-$10.75 10/18/22 Johnson & Johnson narrows FY22 adjusted EPS view to $10.02-$10.07 10/18/22 Johnson & Johnson reports Q3 adjusted EPS $2.55, consensus $2.48 FATE Fate Therapeutics $10.97 / -0.185 (-1.66%) 11/03/22 Fate Therapeutics reports Q3 EPS (86c), consensus (89c) 08/03/22 Fate Therapeutics reports Q2 EPS (79c), consensus (83c) DCT Duck Creek Technologies $11.28 / -0.27 (-2.34%) 01/05/23 Duck Creek Technologies sees FY23 EPS 13c-14c, consensus 12c 01/05/23 Duck Creek Technologies sees Q2 EPS 2c-3c, consensus 3c 01/05/23 Duck Creek Technologies reports Q1 EPS 2c, consensus 0c 10/12/22 Duck Creek Technologies sees FY23 EPS 11c-13c, consensus 12c CTMX CytomX Therapeutics $1.80 / +0.125 (+7.49%) 11/08/22 CytomX Therapeutics reports Q3 EPS (35), consensus (31c) 08/04/22 CytomX Therapeutics reports Q2 EPS (37c), consensus (36c) BVXV BiondVax $3.08 / +0.08 (+2.67%) 11/30/22 BiondVax reports Q3 EPS (NIS 0.02) vs. NIS 0.01 last year BBBY Bed Bath & Beyond $1.69 / -0.725 (-30.08%) 01/05/23 Bed Bath & Beyond sees Q3 net sales of about $1.26B, consensus $1.4B 09/29/22 Bed Bath & Beyond reports Q2 adjusted EPS ($3.22), consensus ($1.85) 09/28/22 Notable companies reporting before tomorrow's open 08/31/22 Bed Bath & Beyond sees Q2 revenue approximately $1.45B, consensus $1.5B AUPH Aurinia Pharmaceuticals $6.88 / +0.165 (+2.46%) 01/06/23 Aurinia Pharmaceuticals backs FY23 net product revenue view $120M-$140M 01/06/23 Aurinia Pharmaceuticals reports preliminary net FY22 revenue $134M 01/06/23 Aurinia Pharmaceuticals reports preliminary Q4 revenue $28.4M, consensus $26.97M 11/03/22 Aurinia Pharmaceuticals lowers FY22 revenue view to $100M-105M from $115M-$135M AEHR Aehr Test Systems $17.28 / -0.62 (-3.46%) 01/05/23 Aehr Test Systems reports Q2 EPS 16c, consensus 8c 10/06/22 Aehr Test Systems backs FY23 revenue view $60M-$70M 10/06/22 Aehr Test Systems reports Q1 EPS 5c vs. (2c) last year 07/19/22 Aehr Test Systems reports Q4 EPS 23c vs. 4c in Q4 last year TSLA MRNA LUV JNJ BBBY AUPH TSLA Tesla $110.35 / -3.3 (-2.90%) 01/06/23 Tesla cuts Model 3, Model Y prices in China after delivery slump, WSJ reports 01/04/23 Tesla files trademark for electric motors 'not for land vehicles,' Electrek says 01/03/23 Tom Zhu becomes Tesla's highest profile executive after Musk, Reuters reports 01/03/23 Tesla fined $2.2M in Korea for violations of advertising law, Bloomberg reports MRNA Moderna $173.53 / -3.87 (-2.18%) 12/24/22 Pfizer, Moderna among vaccine makers to watch in 2023, Barron's says 12/06/22 Pfizer dismisses Moderna claim it copied COVID-19 shot, CNBC reports 10/26/22 Moderna close to U.S. pact to develop Ebola vaccine, Bloomberg says 10/26/22 Moderna close to U.S. pact to develop Ebola vaccine, Bloomberg says LUV Southwest $33.53 / -0.09 (-0.27%) 01/06/23 Southwest meltdown could cost hundreds of millions of dollars, NY Times reports 01/05/23 Southwest to update earnings guidance before Q4 report, Bloomberg says 01/05/23 Southwest to update earnings guidance before Q4 report, Bloomberg says 01/04/23 Southwest offers 25,000 points to travel meltdown-impacted fliers, WSJ reports JNJ Johnson & Johnson $178.77 / -1.39 (-0.77%) 12/04/22 J&J says won't make offer for Horizon Therapeutics, Bloomberg reports 11/07/22 Biogen weighing new CEO options after talks with J&J exec hit impasse, STAT says 10/20/22 CDC panel says COVID shots to be added to regular vaccinations, WSJ says 10/20/22 Drugmakers look to limit Medicare's power to negotiate drug prices, WSJ reports BBBY Bed Bath & Beyond $1.69 / -0.725 (-30.08%) 01/05/23 Bed Bath & Beyond warns it may file for bankruptcy, WSJ says 12/30/22 Bed Bath & Beyond asked by SEC for info on FY21 annual report, Barron's says 11/24/22 Some Bed Bath & Beyond suppliers still owed money, paused shipments, WSJ says 11/04/22 Some Bed Bath & Beyond suppliers restricting, halting shipments, Bloomberg says AUPH Aurinia Pharmaceuticals $6.88 / +0.165 (+2.46%) 01/04/23 Aurinia worth 'keeping closer eye on' after settlement, Dealreporter says TSLA SPRB NVCR MRNA LUV JNJ FATE DCT CTMX BBBY AUPH AEHR TSLA Tesla $110.35 / -3.3 (-2.90%) 01/03/23 What You Missed This Week in EVs and Clean Energy 01/03/23 Fly Intel: Pre-market Movers SPRB Spruce Biosciences $1.26 / +0.03 (+2.44%) 01/05/23 Fly Intel: After-Hours Movers NVCR Novocure $118.46 / +47.98 (+68.08%) 11/29/22 Street Wrap: Today's Top 15 Upgrades, Downgrades, Initiations MRNA Moderna $173.53 / -3.87 (-2.18%) 12/23/22 Buy/Sell: Wall Street's top 10 stock calls this week 12/19/22 What You Missed On Wall Street On Monday 12/19/22 What You Missed On Wall Street This Morning LUV Southwest $33.53 / -0.09 (-0.27%) 12/29/22 What You Missed On Wall Street On Thursday 12/28/22 Fly Intel: Pre-market Movers 12/27/22 What You Missed On Wall Street On Tuesday JNJ Johnson & Johnson $178.77 / -1.39 (-0.77%) 12/05/22 What You Missed On Wall Street On Monday 11/30/22 What You Missed On Wall Street On Wednesday 11/30/22 What You Missed On Wall Street This Morning 11/30/22 Fly Intel: Pre-market Movers FATE Fate Therapeutics $10.97 / -0.185 (-1.66%) 12/22/22 What You Missed On Wall Street On Thursday 12/22/22 What You Missed On Wall Street This Morning 12/22/22 Street Wrap: Today's Top 15 Upgrades, Downgrades, Initiations DCT Duck Creek Technologies $11.28 / -0.27 (-2.34%) 10/12/22 Fly Intel: After-Hours Movers CTMX CytomX Therapeutics $1.80 / +0.125 (+7.49%) 11/21/22 Biotech Alert: Searches spiking for these stocks today 11/10/22 What You Missed On Wall Street On Thursday 11/10/22 What You Missed On Wall Street This Morning BBBY Bed Bath & Beyond $1.69 / -0.725 (-30.08%) 01/05/23 What You Missed On Wall Street On Thursday 01/05/23 What You Missed On Wall Street This Morning 11/14/22 What You Missed On Wall Street On Monday 11/14/22 What You Missed On Wall Street This Morning AUPH Aurinia Pharmaceuticals $6.88 / +0.165 (+2.46%) 01/05/23 Biotech Alert: Searches spiking for these stocks today 01/04/23 What You Missed On Wall Street This Morning 01/03/23 What You Missed On Wall Street On Tuesday 01/03/23 What You Missed On Wall Street This Morning AEHR Aehr Test Systems $17.28 / -0.62 (-3.46%) 10/07/22 What You Missed On Wall Street On Friday 10/07/22 What You Missed On Wall Street This Morning 10/07/22 Fly Intel: Pre-market Movers 01/10/23 Bed Bath & Beyond - BBBY 01/24/23 Johnson & Johnson - JNJ 01/25/23 Tesla - TSLA 01/26/23 Southwest - LUV 01/18/23 Duck Creek Technologies 02/22/23 Duck Creek Technologies, Inc. TSLA MRNA LUV JNJ BBBY AUPH AEHR TSLA Tesla $110.35 / -3.3 (-2.90%) 01/06/23 Notable open interest changes for January 6th 01/05/23 Notable open interest changes for January 5th 01/04/23 Notable open interest changes for January 4th 01/03/23 Notable open interest changes for January 3rd MRNA Moderna $173.53 / -3.87 (-2.18%) 12/22/22 Unusually active option classes on open December 22nd 12/20/22 Early notable gainers among liquid option names on December 20th LUV Southwest $33.53 / -0.09 (-0.27%) 12/30/22 Unusually active option classes on open December 30th 12/29/22 Unusually active option classes on open December 29th 12/28/22 Unusually active option classes on open December 28th 12/27/22 Unusually active option classes on open December 27th JNJ Johnson & Johnson $178.77 / -1.39 (-0.77%) 12/22/22 Johnson & Johnson put volume heavy and directionally bearish 11/11/22 Johnson & Johnson put volume heavy and directionally bearish 10/18/22 Unusually active option classes on open October 18th 09/20/22 Johnson & Johnson put volume heavy and directionally bearish BBBY Bed Bath & Beyond $1.69 / -0.725 (-30.08%) 12/12/22 Unusually active option classes on open December 12th 12/12/22 Largest borrow rate increases among liquid names AUPH Aurinia Pharmaceuticals $6.88 / +0.165 (+2.46%) 07/27/22 Aurinia Pharmaceuticals call volume above normal and directionally bullish AEHR Aehr Test Systems $17.28 / -0.62 (-3.46%) 01/05/23 Aehr Test Systems options imply 9.5% move in share price post-earnings 11/07/22 Aehr Test Systems call volume above normal and directionally bullish 10/06/22 Aehr Test Systems options imply 9.5% move in share price post-earnings

Get Full Fly Access

Breaking market intelligence sent straight to you: Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.

Up-to-date information on important industry events: Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.

News focused on the companies in your portfolio: Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.

14 Day Free Trial